Serum antibodies directed against myelin oligodendrocyte glycoprotein (MOG) are found in
patients with acquired CNS demyelinating syndromes that are distinct from multiple sclerosis …

Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is an
inflammatory demyelinating disease of the central nervous system (CNS) with the presence …

Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) is a spectrum of diseases,
including optic neuritis, transverse myelitis, acute disseminated encephalomyelitis, and …

Background and Objectives Acute inflammatory CNS diseases include neuromyelitis optica
spectrum disorders (NMOSDs) and myelin oligodendrocyte glycoprotein antibody …

Objective Myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) can
be monophasic or relapsing, with early relapse being a feature. However, the relevance of …

Inflammatory myelopathies can manifest with a combination of motor, sensory and
autonomic dysfunction of variable severity. Depending on the underlying etiology, the …

New diagnostic criteria for myelin oligodendrocyte glycoprotein antibody-associated disease
(MOGAD) have recently been proposed, distinguishing this syndrome from other …

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an
inflammatory demyelinating disease that is distinct from multiple sclerosis. Initial …

Background Rituximab (RTX) efficacy in patients with myelin oligodendrocyte glycoprotein
(MOG) antibody-associated disorders (MOGADs) is still poorly understood, though it …

Background To identify factors associated with relapse risk and disability in myelin
oligodendrocyte glycoprotein antibody-associated disorder (MOGAD). Method Between …